Detail akcie India Gbl Cap online

Business Summary: IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
Financial Summary: BRIEF: For the six months ended 30 September 2025, IGC Pharma Inc revenues decreased 24% to $519K. Net loss decreased 16% to $3.4M. Revenues reflect Colombia segment decrease from $2K to $0K. Lower net loss reflects Other income net increase from $43K to $1.4M (income), Valuation of Inventory - Gain/Loss decrease of 50% to $1K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.06 to -$0.04.